Kevin K Zarrabi
Overview
Explore the profile of Kevin K Zarrabi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zarrabi K, Saxena A, Mouw K, Koshkin V, Friedlander T
Am Soc Clin Oncol Educ Book
. 2025 Feb;
45(2):e471924.
PMID: 39913872
Antibody-drug conjugates (ADCs) represent an emerging class of therapeutics across solid tumor oncology and are already positioned as a cornerstone therapy for patients with urothelial carcinoma (UC). In recent years,...
2.
Zarrabi K, Vaishampayan U, Barata P
Eur Urol Focus
. 2025 Jan;
10(6):879-881.
PMID: 39837716
Dysbiosis may hinder effective tumor immunity and reduce the efficacy of therapies such as immune checkpoint blockade (ICB) in renal cell carcinoma (RCC). CBM588, a product containing live Clostridium butyricum,...
3.
Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel-Lindau?
Hochberg A, Gomella P, Im B, Ghosh A, Shah S, Thompson R, et al.
J Kidney Cancer VHL
. 2024 Dec;
11(4):28-38.
PMID: 39678829
Von Hippel-Lindau (vHL) is a hereditary disease characterized by the development of benign and malignant tumors across multiple organ systems. It is seen in approximately 1 in 36,000 live births....
4.
Barata P, Zarrabi K, Bex A, Grivas P, Hermann K, Hofman M, et al.
Eur Urol
. 2024 Dec;
PMID: 39638730
Background And Objective: Advances in molecular diagnostics have ushered in a new era for patients with prostate, renal, and urothelial cancers, with novel radiographic and molecular modalities for the assessment...
5.
Iskandar A, Zarrabi K, Tester W
Can J Urol
. 2024 Sep;
31(4):11921-11930.
PMID: 39217515
Introduction: Renal cell carcinoma is as the most prevalent form of kidney cancer, with the clear cell subtype comprising approximately 75% of cases. The identification of predictive and prognostic biomarkers...
6.
Palecki J, Bhasin A, Bernstein A, Mille P, Tester W, Kelly W, et al.
Cancer Biol Ther
. 2024 May;
25(1):2356820.
PMID: 38801069
Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific antibodies containing two distinct binding domains that allow...
7.
Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma
Eturi A, Bhasin A, Zarrabi K, Tester W
Molecules
. 2024 Apr;
29(8).
PMID: 38675715
Urothelial carcinoma (UC) is the fourth most prevalent cancer amongst males worldwide. While patients with non-muscle-invasive disease have a favorable prognosis, 25% of UC patients present with locally advanced disease...
8.
Zarrabi K, Miron B, Geynisman D
Transl Androl Urol
. 2024 Apr;
13(3):463-466.
PMID: 38590958
No abstract available.
9.
Zorko N, Makovec A, Elliott A, Kellen S, Lozada J, Arafa A, et al.
Prostate Cancer Prostatic Dis
. 2024 Feb;
28(1):129-137.
PMID: 38418892
Background: Natural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to...
10.
Mar N, Dwabe S, Baranda M, Zarrabi K, Eturi A, Gulati S, et al.
Clin Genitourin Cancer
. 2023 Dec;
22(2):217-223.
PMID: 38087703
Introduction: Despite the introduction of various novel therapies for management of metastatic castrate resistant prostate cancer (mCRPC) in recent decades, available treatment options are finite and remain limited. Multiple historical...